There is a risk of patient harm arising through medication error during a transition period where the original and new formulation of Rybelsus ® tablets, which have different stated mg doses but are bioequivalent, will both …
UK Drug Safety Update · December 17, 2025
Rybelsus (semaglutide tablets): transition to new formulation and risk of medication error
Original title: Rybelsus ® (semaglutide tablets): transition to new formulation and risk of medication error
Risk of medication error during transition period when original and new bioequivalent formulations with different stated doses are both in circulation.
Published by UK Drug Safety Update. HealthSignal links to the original document; the summary above is extracted from the source text.